Rhenman & Partners Asset Management AB Boosts Stake in Immunocore Holdings PLC Sponsored ADR $IMCR

Posted by Brenda Bartman on Jun 13th, 2026

Rhenman & Partners Asset Management AB grew its position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) by 442.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 153,278 shares of the company’s stock after acquiring an additional 125,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Immunocore were worth $5,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in IMCR. Leonteq Securities AG purchased a new position in shares of Immunocore during the 4th quarter worth approximately $30,000. Harbour Investments Inc. grew its holdings in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after acquiring an additional 572 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after acquiring an additional 1,700 shares during the period. Finally, State of Tennessee Department of Treasury purchased a new position in shares of Immunocore during the 2nd quarter worth approximately $132,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

Immunocore stock opened at $28.96 on Friday. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $1.47 billion, a P/E ratio of -52.65 and a beta of 0.74. The stock’s 50 day moving average is $29.61 and its 200 day moving average is $32.33. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $27.56 and a twelve month high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. On average, equities research analysts predict that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on IMCR shares. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Monday, April 20th. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Tuesday, April 21st. Mizuho set a $38.00 target price on Immunocore in a report on Thursday, February 19th. Finally, Needham & Company LLC upped their price target on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average price target of $56.71.

Read Our Latest Research Report on IMCR

Immunocore Company Profile

(Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.